1-4 Target

Development of novel bispecific antibodies for cancer therapy targeting the receptor tyrosine kinases ErbB4 and EGFR

Funding period:

01.03.2018 - 28.02.2020

Project description:

The aim is to develop novel human anti-ErbB4 antibodies, which in combination with a humanized anti-EGFR antibody derived from Cetuximab, or as bispecific EGFRxErbB4-targeting antibodies, can be used for the treatment of cancer patients with EGFR- and ErbB4-dependant tumors. At the end of the two-year project, a lead candidate for further preclinical and clinical development as well as information on patient stratification will be available.

  1. Yumab GmbH (Braunschweig), Dr. Thomas Schirrmann
  2. Center of Research and Technological Assistance of Jalisco (CIATEJ), Dr. Mario Alberto Flores und Dr. Abel Gutierrez
  3. RD biotec S.A de C.V (Dr. Marleby García González)
  4. Preclinical Unit of Investigation (UNIPREC), Dr. Isabela Gracia

Project coordination

This image shows Roland Kontermann

Roland Kontermann

Prof. Dr.

Deputy Head of the Institute (Biomedical Engineering)

To the top of the page